timothy sykes logo
TRVI Jumps As Trevi Therapeutics Extends Bullish Run Thumbnail
G Google News

TRVI Jumps As Trevi Therapeutics Extends Bullish Run

BRYCE TUOHEY•UPDATED JUL. 18, 2026, 10:08 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Trevi Therapeutics Inc. stocks have been trading up by 11.6 percent on optimism surrounding its latest clinical trial developments.

What Traders Need To Know

  • Shares surged 10.9% to $19.25 in midday trading on 2026/07/17, signaling strong near-term buying pressure.
  • Earlier that same session, the stock was already up 10.4%, gaining $1.80 to $19.16, showing sustained intraday momentum.
  • Management is meeting institutional investors in London on 2026/07/14 in a Cantor Fitzgerald–hosted non-deal roadshow, boosting visibility with large funds.
  • Recent weekly prices show a steady climb from the mid-$16s into the high-$19s, confirming an active momentum phase.

Candlestick Chart

Weekly Update Jul 13 – Jul 17, 2026: On Saturday, July 18, 2026 Trevi Therapeutics Inc. stock [NASDAQ: TRVI] is trending up by 11.6%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Trevi Therapeutics sits in a classic late‑clinical, pre‑revenue biotech profile: zero debt (total debt‑to‑equity 0), extremely strong liquidity (current ratio ~24.8, quick ratio ~24.1, working capital ~$169M), but negative returns on capital (ROE ~‑34%, ROA ~‑32%) and sizeable quarterly burn (operating cash flow ‑$16.7M, FCF ‑$16.8M). With cash, cash equivalents, and short‑term investments of ~$172M versus modest liabilities, runway is comfortably multi‑year at current spend, supporting ongoing development but not justifying valuation on fundamentals alone given enterprise value of ~$2.5B and persistent losses.

Technically, TRVI is in a strong, momentum‑driven uptrend, with the weekly tape showing a staircase move from ~$16.5 to ~$19.4 and a series of higher closes, confirming aggressive dip‑buying. Intraday 5‑minute candles have shown expanding ranges and strong closes near highs, consistent with institutional accumulation on elevated volume. First actionable level is $18.00–18.20 as near‑term support; a pullback into that zone with volume contraction is a buy setup, with a tight stop below $17.50 to limit downside if momentum breaks.

The recent 10%+ spike on consecutive news items highlighting price strength and a Cantor‑hosted London NDR underscores growing institutional interest, placing Trevi ahead of most micro‑cap biotech peers on sentiment and liquidity but still behind diversified Healthcare benchmarks on profitability and risk‑adjusted return. With its cash runway and institutional engagement, upside skew dominates near term; I see resistance near $21 and initial upside target at $23 over the next 3–6 months, assuming no clinical setbacks.

More Breaking News

Quick Financial Overview

Trevi Therapeutics Inc. (TRVI) is trading like a momentum name right now. Weekly data show the stock opening near $16.50 early in the period and finishing around $19.37, a strong multi-day climb. An intraday 5-minute bar with a push from the high-$17s through $20.22 before closing at $19.07 confirms aggressive buying and a wide trading range, which is exactly the kind of volatility short-term traders look for.

Under the hood, the balance sheet is liquid. TRVI shows about $171.8M in cash and short-term investments, working capital near $169.0M, and a current ratio of roughly 24.8, with minimal debt on the books. That tells traders the company is well funded for now. Enterprise value sits around $2.54B, while book value per share is $1.34 and price-to-book near 10.3, which is rich and signals that the market is paying up for future potential rather than current earnings.

On the earnings side, Trevi Therapeutics Inc. is still firmly in development mode. The latest quarterly numbers show a net loss of about $13.2M, or roughly -$0.09 per share, driven mainly by around $9.9M in research expense and $5.0M in general and administrative costs. Operating cash flow was negative at about -$16.7M, and free cash flow near -$16.8M, with returns on assets and equity both strongly negative. For traders, that means the story is not about current profitability, but about catalysts, sentiment, and the tape.

Conclusion

Trevi Therapeutics Inc. (TRVI) is showing the classic profile of a catalyst-driven biotech swing: heavy upside momentum, expanding ranges, and strong attention from the street. A double-digit intraday gain to $19.25 on 2026/07/17, after already being up 10.4% earlier in the day, tells you buyers are willing to chase strength. The upcoming non-deal roadshow with institutional traders in London, hosted by Cantor Fitzgerald, adds a soft catalyst that may keep interest elevated even without new trial data.

At the same time, the fundamentals remind traders what they are really playing. TRVI has a cash-heavy, low-debt balance sheet, but it is burning over $16M in operating cash per quarter and posting negative returns across the board. Valuation is stretched versus book value, so the downside risk if sentiment flips can be sharp. For active traders, that sets up a pure momentum and trend-following play: manage risk tightly around recent lows and be ready for volatility both ways.

In my view as a trading educator, the key is discipline. The tape says momentum is up, but the financials say this is still a speculative story. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” That mindset is crucial when navigating volatile names like TRVI, where rapid swings can punish emotional decision-making. As I tell my students, “Respect the trend, trade the setup, but never confuse a momentum run with a guarantee of long-term value.” This stock is best approached as a high-beta trading vehicle, not a set-and-forget holding, and any position should be sized and managed with that reality in mind.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”